bigtuna7
Posted - 2 days ago
Rotation back into bios coming… $BCYC $BIIB
Jabed206
Posted - 5 days ago
$BCYC is $20 level good to get in, or could it go further down?
bigtuna7
Posted - 5 days ago
$BCYC Time to get back on the bike
PenkeTrading
Posted - 2 weeks ago
I found you a Bullish Engulfing Candle Pattern on the daily chart of Bicycle Therapeutics Ltd. $BCYC #Bicycle #BullishEngulfingCandle #NASDAQ
erevnon
Posted - 1 month ago
Needham reiterates Bicycle Therapeutics $BCYC at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
BostonDave
Posted - 1 month ago
$BCYC Looks like Morgan Stanley might have sold a large block yesterday.
BostonDave
Posted - 1 month ago
$BCYC 600,000 block sold today. Wonder who?
Doozio
Posted - 1 month ago
Get on YO $bcyc n ride into da weekend during 🧠⏰♾️
BostonDave
Posted - 1 month ago
$BCYC This article is useless, probably written by a bot. https://stocktwits.com/swingingtech/message/588828969
swingingtech
Posted - 1 month ago
$BCYC $VYGR
https://wallstreetwaves.com/bicycle-therapeutics-bcyc-jumps-5-7-whats-next-for-this-stock/
Doozio
Posted - 1 month ago
$BCYC da FUTUre of 🧠⏰ is NOW during 🧠⏰♾️
hope_my_calls_print
Posted - 1 month ago
$BCYC looking very strong since 23s to start the week!
BostonDave
Posted - 1 month ago
$BCYC Oppenheimer has nice things to say about $BCYC https://www.biotechtv.com/post/jay-olson-august-8-2024
Quantumup
Posted - 1 month ago
Oppenheimer reit'd $BCYC OP/$48, after #EANM24 abstracts were released ahead of OPY's annual Radiopharm event, Tuesday, Oct. 8 in NYC. Based on two EANM abstracts, OPY is incrementally optimistic about the potential for BCYC's BRC platform (Bicycle Radionuclide Conjugates):
insiderbuyingselling
Posted - 1 month ago
$BCYC new insider selling: 247 shares. http://insiderbuyingselling.com/?t=BCYC
insiderbuyingselling
Posted - 1 month ago
$BCYC new insider selling: 153 shares. http://insiderbuyingselling.com/?t=BCYC
S_Franconi
Posted - 1 month ago
$BCYC @G101SPM G Can you run this one please?
S_Franconi
Posted - 1 month ago
$BCYC @RamenLives @Mulhollandr
vjtweet
Posted - 2 months ago
$BCYC that's where you buy.
DonCorleone77
Posted - 2 months ago
$BCYC Bicycle Therapeutics presents updated results across oncology pipeline at ESMO Bicycle Therapeutics announced updated Phase 1/2 clinical results for Bicycle Toxin Conjugate zelenectide pevedotin in metastatic urothelial cancer; BTC molecule BT5528 in advanced solid tumors, such as mUC and ovarian; and Bicycle Tumor-Targeted Immune Cell Agonist BT7480 in advanced solid tumors. The company also shared an analysis of peripheral neuropathy, a key adverse event of interest associated with monomethyl auristatin E-based drug conjugates, in patients treated with BTC molecules. These data will be presented during a poster session at the European Society for Medical Oncology Congress 2024 in Barcelona today. Zelenectide pevedotin is a BTC molecule targeting Nectin-4, a well-validated tumor antigen, designed to overcome the significant toxicity associated with other drug conjugate approaches. Updated results from the ongoing Phase 1/2 Duravelo-1 trial evaluating 5 mg/m2 weekly of zelenectide pevedotin monotherapy in 45 mUC patients who had not previously been treated with enfortumab vedotin showed: Among 38 efficacy-evaluable patients, a 45% overall response rate, including 1 confirmed complete response and 16 partial responses. Stable disease was maintained in 9 patients, and 12 patients experienced progressive disease. A median duration of response of 11.1 months among the 14 patients with confirmed responses. An emerging differentiated safety profile, particularly around adverse events of interest such as peripheral neuropathy, skin reactions and eye disorders. Notably, there were no Grade greater than or equal to 3 treatment-related adverse events of peripheral neuropathy, skin reactions or eye disorders, and patients with pre-existing peripheral neuropathy were unlikely to develop worsening peripheral neuropathy during treatment with zelenectide pevedotin. The global Phase 2/3 Duravelo-2 registrational trial of zelenectide pevedotin in patients with mUC is currently enrolling. Additional data updates for zelenectide pevedotin in combination with pembrolizumab in first line mUC and monotherapy in late line triple-negative breast cancer and non-small cell lung cancer are planned for later this year. BT5528 is a BTC molecule targeting EphA2, a tumor antigen that is widely expressed in many cancers and has historically been difficult to target using other drug conjugate approaches. Updated results from the ongoing Phase 1/2 trial evaluating 6.5 mg/m2 every two weeks and 5 mg/m2 weekly of BT5528 monotherapy in patients with advanced solid tumors showed: Among 113 efficacy-evaluable patients, a 12% ORR in patients with advanced solid tumors. The highest anti-tumor activity in mUC, with a 34% ORR in all efficacy-evaluable patients enrolled in the dose escalation and expansion cohorts. Among patients receiving 6.5 mg/m2 every two weeks, a 31% ORR was observed in the dose escalation and expansion cohort and a 45% ORR was observed in the expansion cohort only. A lower but acceptable ORR of 27% was observed in patients receiving 5 mg/m2 weekly. No objective responses in patients with ovarian cancer who received 5 mg/m2 weekly. However, 5 patients maintained stable disease. A suggested correlation between EphA2 expression and response. Among 14 patients with mUC who had available immunohistochemistry and response data, a 43% ORR was observed in EphA2-positive patients compared to a 20% ORR in EphA2-negative patients. A clearly differentiated emerging safety profile, with none of the hemorrhage events or hematological toxicities that have been associated with other EphA2-targeting drug conjugates. The company has begun assessing BT5528 at 6.5 mg/m2 every two weeks in combination with nivolumab. Results from this cohort are expected in 2025. Low rates of treatment-related peripheral neuropathy following monotherapy treatment with BTC molecules zelenectide pevedotin or BT5528. In 149 patients treated with zelenectide pevedotin and 74 patients treated with BT5528 from ongoing Phase 1/2 studies, results showed: TRPN in 28% of patients treated with zelenectide pevedotin and 19% of patients treated with BT5528, nearly all of which were low grade. One Grade 3 event was reported in a patient treated with zelenectide pevedotin following prior therapy with enfortumab vedotin. No Grade 3-4 events were observed for BT5528. Among zelenectide pevedotin-treated patients with peripheral neuropathy at baseline, 80% did not develop TRPN during treatment. TRPN resulted in few dose modifications across the overall patient populations for zelenectide pevedotin and BT5528, and no drug withdrawals were necessary for either BTC molecule. TRPN had completely resolved in 14% and 21% of patients, and 26% and 21%, respectively, had some resolution or improvement at time of reporting, though post-treatment follow-up was limited. Median time to resolution or improvement of TRPN was 2.2 weeks for zelenectide pevedotin and 1.7 weeks for BT5528. The data support the hypothesis that the antibody-drug construct may be a primary driver of peripheral neuropathy rather than MMAE toxicity as was previously believed. BT7480 is a Nectin-4 targeted CD137 agonist designed to overcome immune agonist toxicities and activate the immune system in Nectin-4 expressing tumors. Initial data from the Phase 1/2 dose escalation trial evaluating BT7480 in patients with advanced solid tumors showed: Among 39 patients assigned to receive one of 10 different doses of BT7480, an emerging differentiated safety and tolerability profile with a low number of severe adverse events. Low rates of Grade greater than or equal to3 TRAEs and of treatment-related severe adverse events were reported, with no such events among those receiving the highest dose of 3.5 mg/kg. Best overall response of stable disease in 13 patients, 5 of whom had NSCLC. Stable disease was prolonged in 3 patients, 2 with NSCLC and 1 with anal cancer. There were 2 unconfirmed partial responses, both in patients with cervical cancer. Preliminary biomarker analyses that support BT7480 dual targeting of CD137 and Nectin-4 as demonstrated by enhanced immune cell activation, aligned with the proposed mechanism of action of BT7480. As the maximum tolerated dose for BT7480 has not yet been reached, the company is continuing dose exploration in combination studies, starting with nivolumab.
Stock_Titan
Posted - 2 months ago
$BCYC Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024
https://www.stocktitan.net/news/BCYC/bicycle-therapeutics-presents-updated-clinical-results-across-po0d96j5wocb.html
Stocksrunner
Posted - 2 months ago
Epic Friday Comebacks! 💪🎉$CCCC $GLMD $BCYC $INBS $MCRB Talk about bouncing back! These stocks hit their lows today but fought their way back to close higher. Resilience at its finest! What a way to end the week! Bullish?! 🤔
RonIsWrong
Posted - 2 months ago
$XBI [post is courtesy of the site BPIQ - quite good!!] European Society of Molecular Oncology (ESMO) 2024 Here are 3 clinical trial readouts that could significantly impact the stock prices 📈: $NUVB: Taletrectinib / Phase 2 $MGNX: Vobramitamab / Phase 2 $BCYC: BT8009 / Phase 2/3 #ESMO24 starts September 13 with over 30 cancer clinical trial readouts. See table 📸 for more details below.👇
Fullratio
Posted - 2 months ago
$BCYC quick ratio has surged by 163% YoY and by 45% QoQ: https://fullratio.com/stocks/nasdaq-bcyc/bicycle-therapeutics
KITOVLI
Posted - 2 months ago
$BCYC Visited 52 high @ $27.24. Doesn't seem to be able to break it. No volume.
malky2945
Posted - 2 months ago
$BCYC $SMMT $PCVX since when is early stage data more valuable than an approved drug? this is another part of todays crazy market. $PFE $MRK
